Premium
Phase II Clinical Trial of Recombinant alpha‐2 Interferon for Biopsy‐proven Metastatic or Recurrent Renal Carcinoma
Author(s) -
ROSENTHAL M. A.,
COX K.,
RAGHAVAN D.,
GRYGIEL J. J.,
WINES R. D.,
MAMEGHAN H.,
ROGERS J.
Publication year - 1992
Publication title -
british journal of urology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 0007-1331
DOI - 10.1111/j.1464-410x.1992.tb15594.x
Subject(s) - medicine , nephrectomy , renal cell carcinoma , alpha interferon , carcinoma , performance status , biopsy , alpha (finance) , gastroenterology , interferon , urology , surgery , renal biopsy , oncology , chemotherapy , kidney , immunology , construct validity , patient satisfaction
Summary— Twenty patients with histologically confirmed metastatic or recurrent renal carcinoma were treated in a phase II study with alpha‐interferon (2–5 × 10 6 U/m 2 subcutaneously, 3 times a week). Nineteen patients had multiple sites of disease and 18 had previously undergone nephrectomy; 9 had an ECOG performance status of 0·1, and 11 had a performance status of 2–3. There was one partial response, yielding an overall response rate of 5%. Treatment was well tolerated, although 7 patients developed influenza‐like symptoms, and in 2 cases this was sufficiently severe for the patients to request cessation of treatment. As a single agent at this dose schedule, alpha‐interferon has minimal activity in the treatment of renal carcinoma and cannot be recommended as standard therapy. The difference in outcome between this and some published series may reflect the stringent requirement for histological proof of the presence of metastases.